J C Soria

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
  2. ncbi request reprint [Perspectives and future developments of epidermal growth factor receptors inhibitors]
    Jean Charles Soria
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex
    Rev Pneumol Clin 63:2S18-20. 2007
  3. pmc Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
    Anas Gazzah
    SITEP Service des Innovations Thérapeutiques Précoces, Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France
    Onco Targets Ther 6:95-7. 2013
  4. doi request reprint Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer
    Stephane Vignot
    Institut National de la Santé et de la Recherche Médicale INSERM U981, Villejuif, France
    J Clin Oncol 31:2167-72. 2013
  5. doi request reprint Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
    Jean Charles Soria
    SITEP, Institut Gustave Roussy, South Paris University, Villejuif, France
    Eur J Cancer 49:1815-24. 2013
  6. doi request reprint A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours
    Jean Charles Soria
    Universite Paris XI, SITEP Service des Innovations Thérapeutiques Précoces, Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1799-807. 2013
  7. doi request reprint ERCC1 and RRM1: ready for prime time?
    Benjamin Besse
    Universite Paris Sud, Kremlin Bicetre, France
    J Clin Oncol 31:1050-60. 2013
  8. doi request reprint Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
    J C Soria
    Service des Innovations Thérapeutiques Précoces, Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Ann Oncol 23:463-71. 2012
  9. ncbi request reprint QTc monitoring during a phase I study: experience with SR271425
    Jean Charles Soria
    Institut Gustave Roussy, Villejuif, France
    Am J Clin Oncol 30:106-12. 2007
  10. doi request reprint Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
    J C Soria
    Departement de Medecine, Institut Gustave Roussy, Universite Paris XI, Service des Innovations Thérapeutiques Précoces, 94805 Villejuif, France
    Eur J Cancer 45:2333-41. 2009

Detail Information

Publications116 found, 100 shown here

  1. ncbi request reprint DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...
  2. ncbi request reprint [Perspectives and future developments of epidermal growth factor receptors inhibitors]
    Jean Charles Soria
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex
    Rev Pneumol Clin 63:2S18-20. 2007
  3. pmc Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
    Anas Gazzah
    SITEP Service des Innovations Thérapeutiques Précoces, Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France
    Onco Targets Ther 6:95-7. 2013
    ....
  4. doi request reprint Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer
    Stephane Vignot
    Institut National de la Santé et de la Recherche Médicale INSERM U981, Villejuif, France
    J Clin Oncol 31:2167-72. 2013
    ..We undertook this study to compare genomic alterations identified in archived primary tumors from patients with NSCLC with those identified in metachronous or synchronous metastases...
  5. doi request reprint Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
    Jean Charles Soria
    SITEP, Institut Gustave Roussy, South Paris University, Villejuif, France
    Eur J Cancer 49:1815-24. 2013
    ..This phase I-IIa study was designed to identify the maximum tolerated dose (MTD) and assess safety, antitumour activity, pharmacokinetics and pharmacodynamics of BMS-690514...
  6. doi request reprint A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours
    Jean Charles Soria
    Universite Paris XI, SITEP Service des Innovations Thérapeutiques Précoces, Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1799-807. 2013
    ..AVE1642, a humanised mAb, binds the human IGF-1R specifically and with high affinity. This study aimed to select the dose of AVE1642 alone and then combined with docetaxel 75mg/m(2) (D)...
  7. doi request reprint ERCC1 and RRM1: ready for prime time?
    Benjamin Besse
    Universite Paris Sud, Kremlin Bicetre, France
    J Clin Oncol 31:1050-60. 2013
    ..We will also discuss why the use of both markers should at this point be restricted to clinical research and underline that functional readouts of DNA repair will help boost future strategies for biomarker discovery in the field...
  8. doi request reprint Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
    J C Soria
    Service des Innovations Thérapeutiques Précoces, Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Ann Oncol 23:463-71. 2012
    ..Purpose: We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases...
  9. ncbi request reprint QTc monitoring during a phase I study: experience with SR271425
    Jean Charles Soria
    Institut Gustave Roussy, Villejuif, France
    Am J Clin Oncol 30:106-12. 2007
    ..A phase I trial was conducted to determine the maximally tolerated dose and safety profile, notably cardiac events...
  10. doi request reprint Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
    J C Soria
    Departement de Medecine, Institut Gustave Roussy, Universite Paris XI, Service des Innovations Thérapeutiques Précoces, 94805 Villejuif, France
    Eur J Cancer 45:2333-41. 2009
    ..Masitinib is a tyrosine kinase inhibitor with a pre-clinical profile suggesting greater affinity and selectivity in vitro for the wild-type c-Kit receptor and its juxtamembrane mutation than imatinib...
  11. doi request reprint Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
    Jean Charles Soria
    South Paris University, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:4442-51. 2011
    ..To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC)...
  12. ncbi request reprint Chemoprevention of lung cancer
    Jean Charles Soria
    Departement of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 4:659-69. 2003
    ..Development of a risk model with intermediate endpoints is essential for future chemoprevention studies...
  13. ncbi request reprint Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers
    T Dutu
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 16:1906-14. 2005
    ..To better define the biological characteristics of these tumors, we have compared the expression of a panel of epidermal growth factor receptor (EGFR)-related biomarkers in lung adenocarcinomas from smokers versus those in never-smokers...
  14. doi request reprint ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
    B Besse
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:575-81. 2011
    ..We hypothesised that there might be an increased incidence of BMs in ERCC1-negative non-SCCs when treated with adjuvant cisplatin-based chemotherapy...
  15. pmc BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
    Y Loriot
    Institut Gustave Roussy, UPRES 27 10, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Br J Cancer 103:347-53. 2010
    ....
  16. ncbi request reprint Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
    L Taillade
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1043-50. 2007
    ....
  17. doi request reprint [ERCC1 and lung cancer]
    D Planchard
    Unité Inserm U981, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Rev Mal Respir 27:387-94. 2010
    ..Its use in daily clinical practice requires a further stage of prospective validation studies which are already in progress in patients both with completely resected NSCL or metastatic disease...
  18. doi request reprint A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
    S Postel-Vinay
    1 The Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Institute of Cancer Research, London, UK 2 Département de médecine Unité INSERM 981, Institut Gustave Roussy, Villejuif, France
    Oncogene 32:5377-87. 2013
    ..This study suggests that PARP1/2 inhibitors as a monotherapy could represent a novel therapeutic strategy for NSCLC patients with ERCC1-deficient tumours...
  19. doi request reprint [Targeting KRAS pathway in NSCLC therapy]
    S Le Moulec
    Institut Gustave Roussy, 39 bis, rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:S69-74. 2009
    ..First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC...
  20. ncbi request reprint Targeted therapies in lung cancer
    B Besse
    Department of Medicine, Institut Gustave Roussy, Villejuif
    Ann Oncol 18:ix135-42. 2007
  21. doi request reprint [Molecular targeted therapies in small-cell lung cancer]
    A Levy
    Service des Innovations Thérapeutiques Précoces, Departement de Medecine, Institut Gustave Roussy, Universite Paris XI, Villejuif, France
    Bull Cancer 97:535-45. 2010
    ..However, new targets continue to be identified and many treatments are currently being assessed, including blockade of angiogenesis, signal transduction, cell cycle or induction of apoptosis...
  22. doi request reprint [Molecular aspects of head and neck, and lung cancer oncogenesis]
    Y Loriot
    Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif Cedex, France
    Bull Cancer 96:S13-24. 2009
    ....
  23. doi request reprint Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
    J C Soria
    Lung Cancer Unit, Gustave Roussy Institute, Villejuif, France
    Ann Oncol 20:1674-81. 2009
    ..Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients. RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC...
  24. doi request reprint [Lung cancer: an update in 2010]
    B Besse
    Institut Gustave Roussy, Departement de Medecine, F 94800 Villejuif, France
    Bull Cancer 97:161-9. 2010
    ..Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC...
  25. doi request reprint Added value of molecular targeted agents in oncology
    J C Soria
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:1703-16. 2011
    ..Nevertheless, the use of these agents must be optimised, in part using molecular biomarkers associated with drug response...
  26. ncbi request reprint [Promising targeted molecular therapies for the future years in non-small-cell lung cancer]
    J C Soria
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Rev Pneumol Clin 62:1S35-6. 2006
  27. doi request reprint Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
    C Massard
    Departement de Medecine, Institut Gustave Roussy, University Paris South XI, SITEP, 39, rue Camille Desmoulins, 94805, Villejuif, France
    Invest New Drugs 30:2318-26. 2012
    ....
  28. doi request reprint Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer
    B Besse
    Cancer Medicine Thoracic Unit, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 24:90-6. 2013
    ..This phase Ib study evaluated volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC)...
  29. ncbi request reprint Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
    A Italiano
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Oncol 19:787-92. 2008
    ..There is scarce data concerning outcome and survival of patients enrolled in current phase I oncology trials...
  30. ncbi request reprint [Targeting angiogenesis in oncology]
    J Fayette
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Pathol Biol (Paris) 54:199-205. 2006
    ..The death of neovessels achieved by some of such compounds allows reduction in tumor size. This review describes many angiogenesic inhibitors which mechanisms of action are quite diverse...
  31. ncbi request reprint Targeting angiogenesis with oral agents
    B Besse
    Institut Gustave Roussy, Department of Medicine, Villejuif, France
    Ann Oncol 17:x71-5. 2006
  32. doi request reprint Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
    J C Soria
    Department of Medicine, Institut Gustave Roussy, INSERM Unit 981 and Paris University XI, Villejuif, France
    Ann Oncol 24:20-30. 2013
    ..Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC)...
  33. ncbi request reprint Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
    R Conforti
    Translational Research Unit, Unité Propre de Recherche de l Enseignement Supérieur, équipe d accueil 03535, Villejuif, France
    Ann Oncol 18:1477-83. 2007
    ..The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy...
  34. ncbi request reprint hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
    C Massard
    CNRS UMR8125, Institut Gustave Roussy, Villejuif, France
    Oncogene 25:4505-14. 2006
    ..Altogether, our data indicate that hTERT inhibition may constitute a promising strategy for facilitating the induction of the mitochondrial pathway of apoptosis...
  35. ncbi request reprint Molecular prognostic factors in resectable non-small cell lung cancer
    P Vielh
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Crit Rev Oncol Hematol 53:193-7. 2005
    ..Of special interest are some molecular factors, already or currently tested from a prognostic point of view, that might also become good candidates for predicting treatment efficacy...
  36. doi request reprint Controversies and challenges regarding the impact of radiation therapy on survival
    C Chargari
    INSERM 10 30, Molecular Radiotherapy, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 24:38-46. 2013
    ..In some cases, the survival benefit afforded by radiotherapy is however marginal. The better understanding of the impact of local control on overall survival might allow optimization of clinical trials designs...
  37. ncbi request reprint Expanding role of chemotherapy in lung cancer
    Y Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:x101-7. 2006
  38. ncbi request reprint Molecular targeting: targeting angiogenesis in solid tumors
    J C Soria
    Institut Gustave Roussy, Departement de Medecine, Villejuif, France
    Ann Oncol 15:iv223-7. 2004
  39. ncbi request reprint Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
    K Fizazi
    Institut Gustave Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France
    J Clin Oncol 18:2293-300. 2000
    ....
  40. pmc A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
    F Farace
    Translational Research Laboratory, Institut de Cancerologie Gustave Roussy, 94805 Villejuif, France
    Br J Cancer 105:847-53. 2011
    ..However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay)...
  41. doi request reprint Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
    C A Gomez-Roca
    Departments ofMedicine, SITEP, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Ann Oncol 23:1301-6. 2012
    ..Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies...
  42. doi request reprint [Eruptive nevi associated with sorafenib treatment]
    M Bennani-Lahlou
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Ann Dermatol Venereol 135:672-4. 2008
    ..Cutaneous side effects are frequent with sorafenib, but no naevus modification has been reported until now...
  43. doi request reprint Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
    K A Olaussen
    INSERM, U848, Villejuif, France
    Oncogene 28:4249-60. 2009
    ..Such combinations may lead to a 'collapse' of pro-survival signal transduction pathways that leads to apoptotic cell death...
  44. ncbi request reprint Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    J C Soria
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:1667-70. 2001
    ..The objective of this study was to identify patients more likely to benefit from chemotherapy in order to avoid the indiscriminate treatment of all patients...
  45. doi request reprint Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
    A Osio
    Department of Dermatology, Institute Gustave Roussy, Villejuif, France
    Br J Dermatol 161:515-21. 2009
    ..Much less is known about the chronic cutaneous effects of these drugs and about their potential psychosocial impact on patients...
  46. doi request reprint Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study
    P Blanchard
    SFjRO, French Society of Young Radiation Oncologists, 45 Rue des Saints Peres, 75006 Paris, France
    Eur J Cancer 46:2708-15. 2010
    ..Burnout syndrome occurs frequently amongst oncology healthcare workers. It has a detrimental effect on the patient-physician relationship. Little is known about the prevalence and causes of burnout amongst junior doctors in oncology...
  47. ncbi request reprint High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:518-21. 2007
    ..Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer...
  48. ncbi request reprint Tumour stem cell-targeted treatment: elimination or differentiation
    C Massard
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:1620-4. 2006
    ..Therapies targeting CSC should focus on pathways such as Wnt, Shh and Notch which are required for the maintenance of cancer stem cells, but also on the ABC transporter family and other specific properties of cancer stem cells...
  49. doi request reprint Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
    M Arnedos
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:2293-9. 2012
    ....
  50. pmc Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer
    A Lecharpentier
    University of Paris Sud, INSERM U981 Identification of molecular predictors and new targets for cancer treatment, Institut de Cancerologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Br J Cancer 105:1338-41. 2011
    ..Epithelial-mesenchymal transition (EMT) is considered as an essential process in the metastatic cascade, but there is currently very few data demonstrating directly the existence of the EMT process in CTCs...
  51. doi request reprint Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
    J C Soria
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:2324-32. 2010
    ..In this article, we will evaluate the value of PFS as a primary measure of efficacy for advanced NSCLC, compare the clinical situation with that in other solid malignancies and review the growing number of treatment options for NSCLC...
  52. doi request reprint The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma
    D Planchard
    Medical Oncology and Translational Research, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Ann Oncol 20:1257-63. 2009
    ..It is not known whether ERCC1, RPA and XPF expression levels differ between ever smokers (ES) and never smokers (NS)...
  53. ncbi request reprint [Everolimus (RAD001) and solid tumours: a 2008 summary]
    A Levy
    Departement de Medecine, service des innovations thérapeutiques précoces SITEP, Institut Gustave Roussy, Villejuif
    Bull Cancer 95:1205-11. 2008
    ..Here, we review the preclinical data of this compound with current clinical results and future developments...
  54. ncbi request reprint Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
    F Andre
    Department of Medicine and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:945-51. 2006
    ..In the present study, we evaluated the association between the chemokine receptors expressed in primary tumor cells and the site of metastatic relapse in patients with breast cancer...
  55. doi request reprint [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies]
    G Malouf
    Departement de Medecine, Faculte de Medecine Paris Sud, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Bull Cancer 96:95-101. 2009
    ..Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review...
  56. ncbi request reprint DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs
    E Raymond
    Department of Medicine, Institute Gustave Roussy, Villejuif, France
    Invest New Drugs 18:123-37. 2000
    ..In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery...
  57. doi request reprint Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer
    B Besse
    Department of Cancer Medicine Thoracic Unit, Institut Gustave Roussy, Villejuif
    Ann Oncol 25:409-15. 2014
    ..Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced non-small-cell lung cancer (NSCLC)...
  58. ncbi request reprint Molecularly targeted agents: their promise as cancer chemopreventive interventions
    A Thiery-Vuillemin
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 41:2003-15. 2005
    ..This review article aims to provide a general overview of the potential use of some of these MTA in the chemoprevention setting...
  59. ncbi request reprint Nonapoptotic role for Apaf-1 in the DNA damage checkpoint
    Yael Zermati
    INSERM, U848, 94805 Villejuif, France
    Mol Cell 28:624-37. 2007
    ..Hence, Apaf-1 exerts two distinct, phylogenetically conserved roles in response to mitochondrial membrane permeabilization and DNA damage. These data point to a role for Apaf-1 as a bona fide tumor suppressor...
  60. doi request reprint Gene expression profiling of non-small-cell lung cancer
    Ludovic Lacroix
    Institut de Cancerologie Gustave Roussy, Translational Research Laboratory, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Expert Rev Mol Diagn 8:167-78. 2008
    ..The present review summarizes the main recent advances associated with gene expression analysis in the field of lung cancer and, notably, non-small-cell lung tumors...
  61. ncbi request reprint Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma
    Adriana Handra-Luca
    Hôpital Jean Verdier APHP, Bondy, France
    Clin Cancer Res 13:3855-9. 2007
    ....
  62. doi request reprint Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process
    Christophe Michel Raynaud
    Laboratory of Radiobiology and Oncology, DSV IRCM SRO LRO, CEA, Fontenay aux Roses, France
    Crit Rev Oncol Hematol 66:99-117. 2008
    ..We also discuss various techniques used, and their limitations, in the study of telomeres and genome instability and their role in carcinogenesis and related genomic modifications...
  63. doi request reprint Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma
    Mathilde Wagner
    Departments of Medicine, Institut Gustave Roussy, Paris, France
    J Thorac Oncol 3:677-9. 2008
  64. ncbi request reprint Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:3892-8. 2007
    ..The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT)...
  65. ncbi request reprint [Targeted molecular therapy: the example of Iressa (ZD1839)]
    Jerome Fayette
    Med Sci (Paris) 19:1052-4. 2003
  66. doi request reprint Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers
    Giannis Mountzios
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 14:4096-102. 2008
    ..There are major differences affecting genes in adenocarcinomas in ever and never smokers. However, data on whether mitogen-activated protein kinase (MAPK) activation state differs according to smoking status are limited...
  67. ncbi request reprint [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]
    Antoine Italiano
    Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 94:F177-88. 2007
    ..Clearly, the results of ongoing and future trials are required for an appropriate use of this new class of agents in NSCLC patients...
  68. ncbi request reprint Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2735-40. 2007
    ..The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT...
  69. ncbi request reprint ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial
    Jean Charles Soria
    J Clin Oncol 25:2648-9. 2007
  70. ncbi request reprint ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer
    Ken Andre Olaussen
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    Curr Opin Pulm Med 13:284-9. 2007
    ..Many reports have explored the role of ERCC1 expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells...
  71. ncbi request reprint [Therapeutic implications of epidermal growth factor receptor in lung cancer]
    Jerome Fayette
    Departement de Medecine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 90:S233-40. 2003
    ..In particular it remains to explain why clinical responses do not appear correlated with EGFR expression...
  72. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  73. ncbi request reprint Adjuvant chemotherapy in early-stage non-small cell lung cancer
    Julien Domont
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Semin Oncol 32:279-83. 2005
    ..More recently, modern platinum-containing doublets showed a 10% to 15% overall benefit compared to no adjuvant treatment. In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed...
  74. ncbi request reprint Breast metastasis from lung adenocarcinoma: a case report
    Amine Masmoudi
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Anticancer Res 23:1825-6. 2003
    ..The breast tumor was proved to be of pulmonary origin. Mammary metastases from non-small cell lung cancer are extremely rare and accurate diagnosis is essential to rule out primary breast carcinoma...
  75. ncbi request reprint [Cyclo-oxygenase 2 inhibitors and cancer]
    Thierry Andre
    Bull Cancer 91:S59-60. 2004
  76. ncbi request reprint Imatinib in small cell lung cancer
    Jean Charles Soria
    Division of Medicine, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Lung Cancer 41:S49-53. 2003
    ..Secondary endpoints included assessment of the safety and tolerance of Imatinib, and an analysis of KIT expression in tumor samples...
  77. ncbi request reprint Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features
    Mustafa Erman
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Lung Cancer 47:315-23. 2005
    ..ABAF may be a particularly promising candidate for EGFR-targeted strategies and this possibility merits extensive evaluation in clinical trials...
  78. ncbi request reprint Chemoprevention of lung cancer
    Stephane Vignot
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Recent Results Cancer Res 166:145-65. 2005
    ..New chemoprevention trials are planned with collaborative efforts of researchers involved in fundamental or clinical studies...
  79. ncbi request reprint Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer
    Mustafa Erman
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Semin Radiat Oncol 14:315-21. 2004
    ..In this article, the current status of adjuvant chemotherapy and radiotherapy are reviewed, and future prospects are discussed...
  80. ncbi request reprint Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4575-83. 2004
    ....
  81. ncbi request reprint [Predicting response to Iressa: unexpected mechanism]
    Benjamin Besse
    Med Sci (Paris) 20:750-1. 2004
  82. ncbi request reprint Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer
    Luo Wang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 22:7123-9. 2003
    ..18; 95% confidence interval=0.92, 5.20) after adjustment for age, sex, ethnicity, and smoking status, suggesting a potential role of MNS16A in lung cancer susceptibility. Larger studies are needed to verify our findings...
  83. ncbi request reprint [Adjuvant chemotherapy in non-small cell lung cancer]
    Laurent Taillade
    Comité de pathologie thoracique, Institut Gustave Roussy, Villejuif, France
    Bull Cancer 91:63-7. 2004
    ..In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed...
  84. ncbi request reprint [Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods]
    Amine Masmoudi
    Departement de Medecine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 90:S251-6. 2003
    ..Furthermore, REGF is frequently overexpressed in many epithelial tumors. This review will focus on the rationale and the ongoing research areas related to chemopreventive approaches targeting REGF...
  85. ncbi request reprint NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors
    Béatrice Le Maux Chansac
    Laboratoire Cytokines et Immunologie des Tumeurs Humaines, U487 Institut National de la Santé et de la Recherche Médicale, Villejuif, France
    J Immunol 175:5790-8. 2005
    ..The present study indicates that the MHC-I-deficient lung adenocarcinoma had developed mechanisms of escape from the innate immune response based on down-regulation of NCR and ligands required for target cell recognition...
  86. ncbi request reprint Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer
    Jean Charles Soria
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 9:1785-91. 2003
    ....
  87. ncbi request reprint [PI3K-AKT-mTOR pathway inhibitors]
    Alexis Cortot
    Departement de Medecine, Institut Gustave Roussy, 39, rue Camille Desmoulin, 94805 Villejuif
    Bull Cancer 93:19-26. 2006
    ..The PI3K-AKT-mTOR pathway is a key pathway frequently altered in cancer cells. This manuscript provides an overview of the PI3K-AKT-mTOR pathway and its targeting in human malignancies. A focus is delivered for mTOR inhibitors...
  88. ncbi request reprint [Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient]
    Benjamin Besse
    Departement de Medecine, Institut Gustave Roussy, Villejuif Cedex
    Rev Prat 57:429-40; quiz 440. 2007
  89. ncbi request reprint Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast
    Julien Grenier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif
    Anticancer Res 27:547-55. 2007
    ..Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour. An attempt was made to characterize its differential immunohistochemical and biological profile...
  90. ncbi request reprint Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology
    Michaela Achille
    Department of Medicine, Institut Gustave Roussy, Paris, France
    Clin Lung Cancer 8:214-6. 2006
    ..21 phase III study, suggests that patients should not be selected for erlotinib treatment based only on characteristics, such as smoking status, tumor histology, HER1/EGFR TK mutation status, sex, or ethnicity...
  91. ncbi request reprint [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?]
    Julien Grenier
    Service d Oncologie Medicale, CHU Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Bull Cancer 94:53-61. 2007
    ..Such improvements are especially valuable because inhibitors of EGFR tyrosine kinase are better tolerated than chemotherapy. The exact contribution of monoclonal antibodies like cetuximab is still unclear in NSCLC...
  92. ncbi request reprint Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:6049-55. 2006
    ..Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome...
  93. ncbi request reprint Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation
    Jean Charles Soria
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1178-84. 2002
    ....
  94. ncbi request reprint Telomeres and telomerase as targets for anticancer drug development
    Ken Andre Olaussen
    Laboratory of Radiobiology and Oncology, DSV DRR LRO, CEA, Fontenay aux Roses, France
    Crit Rev Oncol Hematol 57:191-214. 2006
    ..However, we discuss some of the main limits for these approaches of antitumour drug development and why significant work remains before a clinically useful drug can be proposed to patients...
  95. ncbi request reprint Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers
    Jean Charles Soria
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Natl Cancer Inst 95:165-8. 2003
    ....
  96. ncbi request reprint Cyclooxygenase-2 as a target for anticancer drug development
    Jean Baptiste Meric
    Service d Oncologie Medicale, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Crit Rev Oncol Hematol 59:51-64. 2006
    ..Hence, we can state that targeting the COX-2 pathway is a promising strategy in the prevention and treatment of solid tumors. Ongoing trials are expected to answer - at least partly - the remaining questions concerning COX-2 and cancer...
  97. pmc Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth
    Mohammad Obaidul Hoque
    The Head and Neck Cancer Research Division, Department of Otolaryngology, The Johns Hopkins School of Medicine, 818 Ross Research Building, 720 Rutland Ave, Baltimore, MD 21205 2196, USA
    Am J Pathol 168:1345-53. 2006
    ..Although further details on the molecular function of AQP1 related to tumorigenesis remain to be elucidated, our results suggest a potential role of AQP1 as a novel therapeutic target for the management of lung cancer...
  98. ncbi request reprint hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer
    Luo Wang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 8:2883-9. 2002
    ..hTERT may serve as a useful marker to identify patients with poor prognosis and to select patients with early-stage non-small cell lung cancer who might benefit from adjuvant treatment...
  99. ncbi request reprint Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers
    Jean Charles Soria
    Molecular Biology Laboratory, Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:351-5. 2002
    ..The precise meaning of methylated genes in the bronchial brush samples of former smokers must be sought by means of careful follow-up of these individuals...
  100. ncbi request reprint [Chemotherapy of advanced non-small cell lung neoplasms: a closed debate?]
    Yannick Le Guen
    Bull Cancer 90:199-201. 2003
  101. ncbi request reprint Uncertain benefit from surgery in patients with lung metastases from breast carcinoma
    David Planchard
    Division of Cancer Medicine, Gustave Roussy Institut, Villejuif, France
    Cancer 100:28-35. 2004
    ..Isolated lung metastases have been reported to occur in 10-20% of all women with breast carcinoma. The authors described a series of patients who underwent surgery for lung metastases from breast carcinoma...